quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·108d
PRRelease
Gyre Therapeutics Inc. logo

Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

GYRE· Gyre Therapeutics Inc.
Health Care
Original source

Companies

  • GYRE
    Gyre Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 10UpdateJefferies$16.00
  • Aug 26UpdateH.C. Wainwright$18.00
  • Mar 11UpdateNoble Capital Markets-

Related

  • SEC6d
    Amendment: Gyre Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC7d
    SEC Form PRE 14A filed by Gyre Therapeutics Inc.
  • SEC31d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Other Events
  • PR38d
    Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
  • SEC41d
    SEC Form 10-K filed by Gyre Therapeutics Inc.
  • SEC43d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • SEC43d
    Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR43d
    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022